Drug intelligence / Profile preview

AVCN319302a

Development stage: Phase 3
Lead developer: Avicanna
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

AVCN319302a is a preclinical-stage botanical cannabinoid formulation developed by Avicanna for the treatment of chronic pain. It is formulated as an oral powder utilizing Avicanna's proprietary Self-Emulsifying Drug Delivery System (SEDDS) technology, also known as PwdRx. The formulation contains a combination of cannabidiol (CBD) and tetrahydrocannabinol (THC). In preclinical studies, the PwdRx platform has demonstrated significantly enhanced bioavailability, faster absorption, and higher peak plasma concentrations compared to standard medium-chain triglyceride (MCT) oil-based cannabinoid formulations.

Other names: Oral Powder CBD/THC SEDDSPwdRx

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on AVCN319302a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVCN319302a.